DALIAN, China -- China continues to struggle in developing a homegrown mRNA vaccine against COVID-19, with its front-runner failing to reach the market by the end of last year as hoped and now showing disappointing results against the highly infectious omicron variant.
COVID vaccines
China's quest for mRNA vaccine hits stumbling block in omicron
Limited effectiveness of conventional shots puts 'zero-COVID' policy at risk